European Journal of Clinical Pharmacology

, Volume 18, Issue 4, pp 321–326 | Cite as

Pharmacokinetics of sotalol after chronic administration to patients with renal insufficiency

  • G. Berglund
  • R. Descamps
  • J. A. Thomis


Ten hypertensive patients with moderate to severe impairment of renal function were treated with sotalol for 5 to 10 weeks (average 6.4 weeks). Dosage was individually titrated (range 80 to 480 mg daily). The drug was given once daily in the morning. In eight patients blood pressure was satisfactorily controlled. Higher steady-state levels were observed than have been reported after similar doses in patients with normal renal function. The apparent first-order elimination rate constant and plasma clearance were significantly correlated with glomerular filtration rate. For an anuric patient, serum half-life was calculated to be 69 h. In relation to the raised plasma levels, side effects were uncommon. Since sotalol is excreted predominantly via the kidney, therapy in patients with impaired renal function should start with a low dose and any increase in dosage should be made carefully. As the anti-hypertensive effect does not appear to be correlated with the plasma level or with tolerance, adjustment of dose should be based on clinical response.

Key words

sotalol hypertension renal impairment chronic administration pharmacokinetics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anttila M, Arstila M, Pfeffer M, Tikkanen R, Vallinkoski V, Sundquist H (1976) Human pharmacokinetics of sotalol. Acta Pharmacol Toxicol 39: 118–128Google Scholar
  2. Bodem G, Grieser H, Eichelbaum M, Gugler R (1974) Pharmacokinetics of practolol in renal failure. Eur J Clin Pharmacol 7: 249–252Google Scholar
  3. Bröchner-Mortensen J (1972) A simple method for determination of glomerular filtration rate. Scand J Clin Lab Invest 30: 271–274Google Scholar
  4. Dettli L (1977) Elimination kinetics and dosage adjustment of drugs in patients with kidney disease. Prog Pharmacology, Vol 1 No 4. Gustav Fischer, Stuttgart New YorkGoogle Scholar
  5. Garrett E R, Schnelle K (1971) Separation and spectrofluometric assay of the beta-adrenergic blocker sotalol from blood and urine. J Pharm Sci 60: 833–839Google Scholar
  6. Gibaldi M, Perrier D (1975) Drugs and the pharmaceutical sciences, Vol 1: Pharmacokinetic. Marcel Dekker, New York, pp 45–95Google Scholar
  7. Ibsen H, Sederberg-Olsen P (1973) Changes in the glomerular filtration rate during long term treatment with propranolol in patients with arterial hypertension. Clin Sci 44: 129–134Google Scholar
  8. Marquardt D W (1963) An algorithm for least-squares estimation of non-linear parameters. J Soc Ind Appl Math 11: 431–440Google Scholar
  9. McDevitt D G, Shanks R G (1977) Evaluation of once daily sotalol administration in man. Br J Clin Pharmacol 4: 153–156Google Scholar
  10. Parvinen I, Paukkala E (1979) Comparison of once and twice daily administration of sotalol in the treatment of hypertension. Eur J Clin Pharmacol 15: 293–298Google Scholar
  11. Sassard J, Pozet N, McAinsh J, Legheand J, Zech P (1977) Pharmacokinetics of atenolol in patients with renal impairment. Eur J Clin Pharmacol 12: 175–180Google Scholar
  12. Shanks RG (1966) Methods for the evaluation of beta-adrenoceptor antagonists. In: Mantegazzi P, Picinini F (eds) Methods of drug evaluation. North Holland, Amsterdam, pp 118–126Google Scholar
  13. Shaw H L (1977) Once daily sotalol in the treatment of hypertension. J R Coll Gen Pract 27: 752–745Google Scholar
  14. Simpson F O (1974) Beta-adrenergic blocking drugs in hypertension. Drugs 7: 85–105Google Scholar
  15. Sundquist H, Anttila M, Arstila M (1974) Antihypertensive effects of practolol and sotalol. Clin Pharmacol Ther 16: 465–472Google Scholar
  16. Sundquist H (1976) Pharmacokinetics and hypertensive effect of the beta-blocker sotalol. Jaakko-Taara Oy, TurkuGoogle Scholar
  17. Tjandramaga T B, Thomas J, Verbeeck R, Verbesselt R, Verberckmoes R, de Schepper P J (1976) The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol. Br J Clin Pharmacol 3: 259–265Google Scholar
  18. Tuomilehto J, Arstila M, Sarilahti R, Sundquist H (1977) Sotalol and a combination of hydrochlorothiazide and spironolactone in the treatment of hypertension with a single daily dose. Curr Ther Res Clin Exp 21: 668–675Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • G. Berglund
    • 1
  • R. Descamps
    • 2
  • J. A. Thomis
    • 2
  1. 1.Department of Medicine, Sahlgren's HospitalUniversity of GöteborgSweden
  2. 2.Faculty of PharmacyUniversity of GentBelgium

Personalised recommendations